Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2013
Price :
$35
*
At a glance
- Drugs OX 914 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Orexo
- 25 Mar 2009 Primary endpoint 'Total nasal symptom score' has not been met; results reported in an Orexo media release.
- 13 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2008 Status changed from recruiting to active, no longer recruiting.